Pharmaceutical assets
Cannabinoid formulations advanced through defined regulatory pathways, beginning with CannEpil®.
Cannabinoid health sciences platform
Where Science Meets
Cannabinoid Innovation
Endovia Health Sciences is building a diversified cannabinoid health sciences platform through pharmaceutical innovation, strategic partnerships and disciplined execution.
NYSE American
EDVA
View the live EDVA quote on NYSE American ↗
Shares trade as EDVA on NYSE American. Endovia does not publish or maintain price data on this site; quotes are available from NYSE American and other market-data sources and may be delayed.
The platform
Three growth engines, one scientific standard.
Endovia acquires, develops and commercializes differentiated cannabinoid health technologies across pharmaceutical, veterinary and consumer wellness markets.
01 / PHARMACEUTICAL
02 / THERAPEUTICS
Human and veterinary therapeutics
A dual development strategy that applies the same formulation science to people and to companion animals.
03 / WELLNESS
Wellness and beverages
Consumer wellness formulations and functional beverages, built on the beverage and distribution platform the company already operates.
Asset progression
How programs move through the platform.
Programs advance through the same four stages, from sourcing and formulation to regulatory pathway and commercialization. The four CannEpil® programs below are the company's current development and access tracks. Select a row for its regulatory and commercial status.
Advanced
Current focus
Planned
Note on stage indicators
Stage indicators and program status are supplied by the company and must remain consistent with its SEC filings. Expand a row for the regulatory and commercial status of that program. Stage is not a representation of approval: programs described as investigational have not received marketing authorization in the jurisdictions noted.
Flagship asset
CannEpil®
Endovia's first pharmaceutical cannabinoid asset and the proof point for the platform — a formulation program with international access pathways, a veterinary development track and human pharmaceutical opportunities under evaluation.
- Asset class
- Cannabinoid pharmaceutical formulation
- Markets
- Human and veterinary Confirm
- Access
- International pathways Confirm
- Regulatory status
- — Counsel review
Investor gateway
Built for the people who diligence us.
Filings, governance and milestone news in one place — sourced directly from authoritative systems rather than maintained by hand.
Latest news
Milestones, not noise.
- — Announcements appear here from the company's Current Reports on Form 8-K Feed pending
Vision
To build a diversified cannabinoid health sciences platform that translates science into regulated therapies and trusted health and wellness products for people and animals.
Mission
Acquire, develop and commercialize differentiated cannabinoid health technologies across pharmaceutical, veterinary and consumer wellness markets.
Executive team
Operators with public-company experience.
Leadership across pharmaceutical development, capital markets, regulatory affairs and commercial execution.
Officer roster as confirmed by the company. The biography and headshot of the interim Chief Financial Officer are to follow. Biography to follow
Board of directors
The directors accountable for oversight.
Biographies as supplied by the company. Independence determinations and committee membership are published on the corporate governance page.
Board roster and biographies as confirmed by the company. One headshot is to follow; independence determinations are confirmed against the proxy statement. Headshot to follow
Board composition
Independent oversight, documented practices.
Board composition, committee membership and governance practices are published in full on the corporate governance page, alongside the charter, bylaws, committee charters and Board-adopted policies.
Independence
Majority-independent board with defined independence standards. Confirm
Committees
Audit, Compensation, and Nominating & Governance committees.
Relevant expertise
Pharmaceutical development, capital markets, regulatory and commercial operations.
Contact the Board
A published channel for shareholders to reach the independent directors.
Scientific and development partners
Capability through partnership.
Endovia advances its programs with scientific and development partners selected for demonstrated capability and execution rather than breadth.
PARTNER
Lupvindol Biosciences
Veterinary pharmaceutical development and regulatory partner. Endovia has entered into a strategic development collaboration with Lupvindol Biosciences to advance CannEpil® through the U.S. FDA Center for Veterinary Medicine pathway for companion-animal oncology and chronic pain management.
Lupvindol leads scientific development and FDA regulatory activities, including the planned INAD process, product development plan and required studies. Endovia provides milestone-based development funding and retains ownership of the medical technology, study data, regulatory submissions and foreground intellectual property generated through the collaboration, as well as lead responsibility for commercialization and strategic partnering.
CAPABILITY
Formulation and manufacturing
Contract development and manufacturing relationships supporting pharmaceutical-grade production.
CAPABILITY
Clinical and regulatory
Advisors and service providers supporting regulatory strategy across target jurisdictions.
Flagship asset
CannEpil®
A cannabinoid pharmaceutical formulation and the company's first commercial-stage asset. Endovia is advancing CannEpil® through international access pathways while evaluating human pharmaceutical and veterinary development opportunities.
01
Product overview
CannEpil® is a pharmaceutical-grade cannabinoid formulation comprising cannabidiol (CBD) and tetrahydrocannabinol (THC) isolates in an oral liquid solution manufactured under European Union Good Manufacturing Practice standards.
Originally developed for drug-resistant epilepsy in humans, CannEpil has an established history of patient access in selected international markets. Endovia holds exclusive global development and commercialization rights to CannEpil within its licensed fields, which include human neurological indications and veterinary applications.
CannEpil is being developed as a platform asset with three distinct opportunities: international patient access and commercialization, continued human pharmaceutical development, and FDA-regulated veterinary development.
02
Indications & markets
Current international access
Drug-Resistant / Refractory Epilepsy — Human. CannEpil has previously been supplied to patients with severe treatment-resistant epilepsy through regulated patient-access pathways in Ireland, the United Kingdom and Australia. These pathways should not be characterized as general marketing approvals.
Investigational developmentDrug-Resistant / Refractory Epilepsy — Human. CannEpil remains an investigational pharmaceutical candidate for formal regulatory approval in major markets, including the United States. The U.S. program has completed pre-IND engagement with the FDA and has been assigned an IND application number; additional development work is required before U.S. clinical advancement.
Companion-Animal Oncology — Veterinary. CannEpil is being developed as an investigational veterinary product for potential use in companion-animal oncology, initially focused on canine applications.
Companion-Animal Chronic Pain — Veterinary. CannEpil is also being developed for potential use in chronic pain management in companion animals.
The veterinary program is intended to proceed through the FDA Center for Veterinary Medicine’s Investigational New Animal Drug (INAD) and Conditional Approval pathway.
Target commercial marketsEndovia’s current commercial priorities include the United Kingdom and Ireland, where CannEpil® has established patient-access history, together with selected Latin American markets where the Company intends to activate existing commercial and distribution relationships.
Additionally, the Company intends to pursue the commercialization of CannEpil® in the United States for veterinary and human indications, subject to obtaining all required regulatory approvals.
03
International access
Ireland
CannEpil has been made available through Ireland’s Medicinal Cannabis Access Programme (MCAP). The Irish framework permits prescribing of qualifying cannabis-based products in specified circumstances, and CannEpil has historically benefited from reimbursement-supported access. MCAP access is distinct from a conventional marketing authorization.
United KingdomCannEpil has been supplied through the United Kingdom’s Named Patient Request pathway for patients with severe treatment-resistant epilepsy. Company disclosures state that authorization for importation and prescription was granted through the applicable UK regulatory framework.
AustraliaCannEpil has previously been supplied through Australian early- or special-access pathways. Argent Biosciences, the Australian licensor of CannEpil, currently identifies Australia, Ireland and the United Kingdom as markets in which CannEpil has previously been sold or supplied through early-access mechanisms.
Latin AmericaEndovia is evaluating the relaunch of CannEpil through existing commercial relationships in selected Latin American jurisdictions. Availability will remain subject to country-specific regulatory, importation, prescribing and distribution requirements.
04
Regulatory status & safety
CannEpil is not FDA-approved for human or veterinary use in the United States.
For human development in the United States, the program has completed FDA pre-IND engagement and has been assigned an Investigational New Drug application number. Assignment of an IND number should not be described as FDA clearance of an active IND or authorization to commence a U.S. clinical trial.
For veterinary development, Endovia and its development collaborator intend to pursue the FDA Center for Veterinary Medicine INAD and Conditional Approval pathway. The veterinary product remains investigational and has not received FDA approval.
CannEpil has generated human-use and safety data through prior studies and international patient access. A randomized controlled study involving 31 healthy participants evaluated acute CannEpil dosing and simulated driving performance; Argent Biosciences reported that the findings were compatible with a favorable safety profile. Additional preclinical and clinical work is required to establish safety and efficacy for regulatory approval in the proposed human and veterinary indications.
Important notice
CannEpil is an investigational product in jurisdictions where it has not received marketing authorization. Statements regarding investigational indications are not claims of established safety or efficacy. Access, prescribing and reimbursement vary by jurisdiction.
Product architecture
Four tracks from a single asset.
CannEpil® anchors a structure designed to add assets without redesigning the platform around them.
TRACK 01
International commercialization
Expanding availability through established access pathways and distribution partners.
TRACK 02
Veterinary development
Applying the same formulation science to companion-animal health programs.
TRACK 03
Human pharmaceutical opportunities
Evaluating regulatory pathways for human pharmaceutical development.
TRACK 04
Future products and pipeline
Acquisition and in-licensing of differentiated cannabinoid technologies.
Pipeline
Additional assets appear here as programs are announced.
The product section is structured to add pipeline candidates without a redesign.
Regulatory and medical disclaimer
Information on this page is provided for general corporate and investor information only. It is not medical advice, a prescribing resource, or an offer to sell or a solicitation to buy any product. Nothing on this page should be read as a claim that any Endovia product is safe or effective for any use, or that it has been approved by the U.S. Food and Drug Administration or any other regulator. Product availability, regulatory status and permitted use differ by jurisdiction. Approved use, investigational use and international access programs are separate and are described separately.
CannEpil® is a registered trademark. All product copy on this page requires review by regulatory and securities counsel before publication.
Financial statements
Filings and reports.
Every filing the company makes is available on the SEC's EDGAR system. Open the EDGAR filing index →
Annual and quarterly reports, current reports and downloadable PDFs, linked directly to the authoritative source.
- Annual reports on Form 10-K
- Quarterly reports on Form 10-Q
- Current reports on Form 8-K
- Proxy statements and Section 16 filings
- Historical filings under Splash Beverage Group, Inc.
| Form | Period | Filed | |
|---|---|---|---|
| Annual report on Form 10-K | — | — | View |
| Quarterly report on Form 10-Q | — | — | View |
| Quarterly report on Form 10-Q | — | — | View |
| Current report on Form 8-K | — | — | View |
| Proxy statement (DEF 14A) | — | — | View |
| Filings under Splash Beverage Group, Inc. Filings made before the name change, same SEC registrant | Through — | — | EDGAR |
All filings, before and after the name change, are on EDGAR under the same registrant and are linked here rather than maintained by hand. Dates populate from the EDGAR feed once connected. Integration pending
SEC registrant CIK — 0001553788 — unchanged by the name change.
News and events
Announcements and the investor calendar.
- —Announcements appear here from the company's Current Reports on Form 8-KFeed pending
Announcements are drawn from the company's Current Reports on Form 8-K as filed with the SEC. Press releases that are not furnished as an exhibit to a Form 8-K will not appear here; the authoritative record is EDGAR.
Corporate governance
Governance statement.
The Board of Directors oversees the management of the company on behalf of shareholders, and holds itself to the standards it publishes.
Endovia Health Sciences is governed by a Board of Directors operating under a written charter and bylaws, with three standing committees — Audit, Compensation, and Nominating and Corporate Governance — each functioning under its own published charter.
The Board determines director independence under the applicable exchange listing standards, reviews related-person transactions, and oversees the company's Code of Business Conduct and Ethics, its Insider Trading Policy and its procedures for reporting accounting and auditing concerns.
The company publishes its governing documents in full rather than in summary. Where a description on this site differs from a governing document or an SEC filing, the document or filing governs.
Governance statement to be reviewed and adopted by the Board before publication. Draft — Board approval
Board composition
Directors, independence status, committee membership and areas of expertise. Roster to confirm
Committees
Audit, Compensation, and Nominating and Corporate Governance, each operating under a published charter.
Charters and policies
Charter and bylaws, committee charters, Code of Business Conduct and Ethics, and the Insider Trading Policy.
Contact the Board
Shareholders may write to the independent directors through investor relations.
Investor resources
Stay on the list.
Get filings, announcements and event notices by email as they are published.
Enter a valid email address.
Sign-ups are recorded now. Distribution of alerts is pending selection of the company's investor relations provider. Distribution pending
Investor FAQs
Share count, fiscal calendar, exchange listing and ticker transition.
Transfer agent
VStock Transfer, LLC
18 Lafayette Place, Woodmere, NY 11598
(212) 828-8436
vstocktransfer.com
Share transfers, lost certificates and account questions.
Investor relations contact
Analyst coverage
Firms publishing research on the company, where applicable.
Compliance note
Stock price, volume and market capitalization are supplied by a third-party market-data provider and may be delayed. Endovia does not manually maintain price data and does not warrant its accuracy or timeliness. Filings shown here link to the authoritative versions on the SEC's EDGAR system; if a summary on this site differs from a filed document, the filed document governs.
Forward-looking statements. Statements on this website that are not historical facts are forward-looking statements, including statements about strategy, product development, partnerships and anticipated milestones. Forward-looking statements involve known and unknown risks and are subject to change. Actual results may differ materially. See the risk factors in the company's most recent Annual Report on Form 10-K and subsequent filings. Endovia undertakes no obligation to update forward-looking statements except as required by law.
Nothing on this page is an offer to sell or a solicitation of an offer to buy any security.
Documents
Charter, bylaws and Board policies.
Each document is posted as a downloadable PDF and replaced in full when amended, rather than summarized.
| Document | Adopted or amended | |
|---|---|---|
| Certificate of Incorporation, as amended | — | |
| Amended and Restated Bylaws | — |
| Charter | Adopted or amended | |
|---|---|---|
| Audit Committee Charter | — | |
| Compensation Committee Charter | — | |
| Nominating and Corporate Governance Committee Charter | — |
| Policy | Adopted or amended | |
|---|---|---|
| Insider Trading Policy | — | |
| Code of Business Conduct and Ethics | — | |
| Whistleblower and complaint procedures | — | |
| Compensation recovery (clawback) policy | — | |
| Related-person transactions policy | — |
Documents are supplied by the company and posted as executed. Confirm the final list, adoption dates and which policies are posted versus filed as exhibits. Counsel review
Board of directors
Composition and committee membership.
Independence is determined by the Board under the applicable exchange listing standards. Biographies are published on the About us page.
| Director | Role | Independent | Audit | Compensation | Nom. & Gov. |
|---|---|---|---|---|---|
| F. William Caple | Chair | Yes | Member | Chair | Chair |
| Frank Knuettel II | Director | Yes | Chair | Member | Member |
| Thomas Fore | Director | Yes | — | Member | — |
| Brady J. Cobb | Director, Interim CEO | No | — | — | — |
Swipe the table to see the committee columns.
Independence is determined by the Board under the applicable exchange listing standards. Mr. Cobb is not independent by virtue of his service as an executive officer. A dash indicates the director is not a member of that committee. Committee composition is confirmed against the proxy statement.
Committees
Three standing committees.
Audit
Chair — Frank Knuettel II
Oversees financial reporting, internal controls, the independent auditor and the complaint procedures for accounting matters.
Compensation
Chair — F. William Caple
Reviews executive compensation, equity plans and the compensation recovery policy.
Nominating and Corporate Governance
Chair — F. William Caple
Recommends director nominees, reviews Board composition and oversees governance practices.
Each committee's responsibilities are set out in its charter above; the descriptions here are summaries only.
Contact the Board
Writing to the independent directors.
Shareholders and other interested parties may communicate with the Board, the non-management directors as a group, or an individual director. Correspondence is forwarded unopened to the addressee.
Concerns about accounting, internal controls or auditing matters may be submitted to the Audit Committee under the whistleblower procedures published above.
By mail
Board of Directors, c/o Corporate Secretary
Endovia Health Sciences
1112 N. Flagler Drive
Fort Lauderdale, Florida 33304
By email
investors@endoviasciences.com
Marked for the attention of the Board.
Investor relations
Investors and analysts
Investor inquiries, press-kit requests, analyst and fund outreach.
investors@endoviasciences.comBusiness development
Partners and distributors
Licensing, pharmaceutical partners and commercial distribution.
bd@endoviasciences.comMedia
Press and interviews
Press requests, interviews and corporate background.
media@endoviasciences.comHuman resources
Careers and employment
Open roles, applications and employment verification.
hr@endoviasciences.comCorporate office
By phone or mail
1112 N. Flagler Drive
Fort Lauderdale, Florida 33304
United States
Send a message
Contact Endovia.
Choose a topic and your message is routed to that desk. Please do not include confidential or material non-public information.
By phone
Main — (954) 999-5446
Enter your name.
Enter a valid email address.
Choose a topic.
Enter a message.
Messages are routed by topic to the investor relations, business development, media, human resources or general desk. Please allow one business day for a reply.